279 related articles for article (PubMed ID: 25519042)
1. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
2. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
3. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
[TBL] [Abstract][Full Text] [Related]
4. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
7. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
9. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
12. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.
Jing Y; Chavez V; Khatwani N; Ban Y; Espejo AP; Chen X; Merchan JR
Cancer Gene Ther; 2020 Dec; 27(12):910-922. PubMed ID: 32231231
[TBL] [Abstract][Full Text] [Related]
14. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
16. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
18. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
19. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
[TBL] [Abstract][Full Text] [Related]
20. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]